COMP <GO>
CORT vs SYRE // PIOTROSKI F-SCORE QUALITY
Corcept Therapeutics Incorporated (NASDAQ) VS. Spyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CORT 3
— SYRE 5
▲ PIOTROSKI F-SCORE QUALITY LEADER: CORT
LAST: $85.95 (-0.38%) • MKT CAP: $9.29B
piotroski-score
8/9
LAST: $98.96 (-0.79%) • MKT CAP: $10.33B
piotroski-score
5/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. SYRE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | SYRE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | -20.00% | +24.80 | CORT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | -1.64% | +3.17 | CORT | /fcf-yield <GO> |
| Operating Margin | 5.90% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 13.10% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 17.60% | -4.80 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 5/9 | +3.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 61.9 | -31.00 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.89 | -0.01 | SYRE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 22.0x | +56.30 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.29B | $10.33B | -$1.04B | SYRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | SYRE REV | CORT GROSS % | SYRE GROSS % | CORT FCF | SYRE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $0 | 98.3% | — | $141.8M | -$169.3M |
| FY 2024 | $675.0M | $0 | 98.4% | — | $196.1M | -$157.4M |
| FY 2023 | $482.4M | $886.0K | — | — | $105.0M | -$99.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
SYRE // BETA 0.89